Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Corcept Therapeutics Inc Market Cap
From what 6 stock analysts predict, the share price for Corcept Therapeutics Inc (CORT) might increase by 74.65% in the next year. This is based on a 12-month average estimation for CORT. Price targets go from $23.00 to $61.00. The majority of stock analysts believe CORT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Corcept Therapeutics Inc has a total of 6 Wall St Analyst ratings. There are 5 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Corcept Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| joon lee Truist Financial | Buy | $42.0 | maintained | Feb 16, 2024 |
| david amsellem Piper Sandler | Buy | $35.0 | reiterated | Jan 23, 2024 |
| roanna ruiz Leerink Partners | Hold | $23.0 | maintained | Jan 22, 2024 |
| matthew kaplan Ladenburg Thalmann & Co. | Buy | $61.0 | maintained | Jan 16, 2024 |
| edward nash Canaccord Genuity | Buy | $38.0 | maintained | Jan 8, 2024 |
| swayampakula ramakanth H.C. Wainwright | Buy | $28.0 | maintained | Jan 2, 2024 |
| greg fraser Truist Financial | Hold | $26.0 | maintained | May 26, 2023 |
| dennis ding Jefferies | Hold | $22.0 | rated | Feb 14, 2023 |
| michelle gilson Canaccord Genuity | Buy | $30.0 | initiatedcoverage | Feb 2, 2022 |
| chris howerton Jefferies | Hold | $16.0 | downgraded | Aug 5, 2020 |
| charles duncan Cantor Fitzgerald | Hold | $15.0 | reiterated | Feb 21, 2020 |
| adam walsh Stifel Nicolaus | Hold | None | maintained | Feb 10, 2020 |
| david buck B.Riley Financial | Hold | $12.0 | maintained | Feb 26, 2019 |
| corey davis Seaport Global | Buy | $25.0 | reiterated | Aug 9, 2018 |
| christopher james Ladenburg Thalmann & Co. | Buy | $20.0 | maintained | Jul 18, 2017 |
| debjit chattopadhyay Guggenheim | Sell | $7.0 | initiatedcoverage | Dec 20, 2016 |
| tazeen ahmad Bank of America Securities | Sell | $5.0 | reiterated | Jun 2, 2016 |
| roy buchanan JMP Securities | Buy | $8.0 | initiatedcoverage | Dec 16, 2015 |
| annabel samimy Stifel Nicolaus | Hold | None | downgraded | Jan 13, 2014 |
| ravi mehrotra Evercore ISI | Hold | $2.0 | downgraded | Aug 9, 2013 |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
When did it IPO
2004
Staff Count
352
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Joseph K. Belanoff M.D.
Market Cap
$2.34B
In 2023, CORT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CORT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NMIH-USD
$29.05
BLMN-USD
$26.6
JBLU-USD
$7.01
$73.03
APPN-USD
$32.98
PLUG-USD
$3.96
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
